Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Source: CNBC Business
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at CNBC Business